Innovation for

Reproductive Success

About Ostara Biomedical

Ostara Biomedical specialises in developing products to improve the success rates of artificial reproduction in mammals, from domestic livestock to laboratory rodents. Ostara’s suite of ProgenySys™ products offers users substantial cost savings, while addressing ethical concerns by significantly reducing the numbers of animals needed in breeding programmes.

The Company’s innovative ProgenySys™ technology will initially focus on the production of transgenic rodents which are used globally for medical research across a wide range of disease states. ProgenySys™  is also being developed to target significant opportunities in livestock production where it will aim to reduce inefficiencies in the global food chain.


Management Team

Dr Nadia GopichandranChief Executive Officer & Co-Founder

Nadia is co-founder of Ostara Biomedical and co-inventor of its core technology. She has over fifteen years' experience of research in reproductive biology. She holds a PhD in early embryo biochemistry from the University of York and worked for five years as a post-doctoral researcher in reproductive medicine at the University of Leeds, focusing on the immunological mechanisms involved in infertility and a number of obstetric and paediatric conditions. Nadia has contributed to a number of University spin out companies focused in the human IVF sector, pregnancy related disorders and artificial reproduction in animals, and has overall responsibility for delivery of the ProgenySys™ platform.

Dr Sarah Field, Technical Director

Sarah earned her PhD in Reproductive Physiology from the University of Leeds, focusing on the endometrial response to mating at a systems biology level. Sarah has co-authored several publications in international journals such as BMC Systems Biology and Reproduction, and maintains collaborations with prestigious research centres such as Harvard Medical School. She has commercial experience from several sectors, firstly contributing to R&D in animal foodstuffs at the Waltham Centre for Pet Nutrition (Mars UK). Sarah manages Ostara's development programme and the relationships with collaborators

Dr David Danson, Chairman

David is a veterinarian with significant experience in general practice and industry, which include Marketing Director, Europe for Solvay Animal Health, Director, Global Marketing for the US-based pharmaceutical Group, Mallinckrodt, CEO then Chairman of the Lausanne-based, Biokema SA and CEO of UA Group plc, an AIM-listed property company where the share price rose from £1.35 to £14.70 in his 8 year’s tenure. David  is currently Deputy Chairman of Council at The Royal Veterinary College in the University of London and has a portfolio of Non-Executive directorships including Eco Animal Health Group plc, a veterinary pharmaceutical company, and Moredun Scientific Ltd, a contract research company.

Richard Smith, Chief Financial Officer

Richard is a qualified chartered accountant (ACA). An experienced Group Financial Controller, he has held numerous finance director positions in both large multinationals and SMEs including Advanced Medical Solutions and Astra Zeneca. Richard’s expertise covers financial planning and analysis, acquisitions, disposals, business valuation and intellectual property. His experience as a business partner to life science and healthcare companies provides Ostara with sound financial management.

Dr Nic Orsi, Scientific Advisor & Co-Inventor

Nic is an Academic Clinical Fellow in Histopathology at St James's Hospital (Leeds) and a Visiting Fellow/Lecturer at both Harvard Medical School and the University of Leeds. After graduating in Animal Science (Reading), he pursued his combined interests in biochemistry and reproduction earning a PhD in early mammalian embryo development (York). Nic has extensive experience in the commercialisation of diagnostic/prognostic biomarkers and innovations aimed at improving pregnancy rates in both veterinary and clinical arenas.

Dr Andy Round, Commercial Advisor

Andy is Investment Director at MSIF where his responsibilities include deal sourcing, making and closing investments and then managing portfolio companies to successful exits. Andy has experience of both sides of the funding process, having invested in and built up a portfolio of life sciences companies at both SPARK Impact and IP-Group and having raised £30-40 Million for a range of early stage companies and Ventures. Andy has a PhD in Biochemistry and his work became the foundation on which a North West Biotechnology company was founded, Micap which went on to
be listed on AIM.

Investor Relations

Ostara Biomedical was founded in 2012 to target the significant opportunities in improvement of success rates in artificial reproduction across a range of mammalian species.

 Its initial products target the production of transgenic rodent models, which are used globally for medical research across a wide range of diseases. The total global ‘Mice Model Market’ in 2016 was estimated at £1.1 billion, with a CAGR of 7.5% . There are significant opportunities in this market, which continually assesses new innovations in the search for technologies that can increase efficiencies and reduce costs by streamlining breeding systems to increase animal welfare  and to reduce the overall numbers of animals used.

Ostara’s Capital Structure

Venture Capital


Angel Investors

9 High Net Worth Individuals


Equity & Options

Ostara’s has shareholders that include venture funds, angel investors , founders and management. £1.6m has been raised to date in equity investment; £1.1m from The North West Fund for Biomedical managed by SPARK Impact and £430k from private investors. Ostara has also secured an additional £810k in grant awards from Innovate UK, the UK government’s innovation agency, NC3Rs and a collaborative BBSRC award.

Intellectual Property

Ostara believes in building shareholder value by protecting its investments in innovative research through registration of its intellectual property in key target markets. It has a strong and comprehensive IP portfolio covering its core ProgenySys™ technologies, which includes:

  • Granted UK patents GB2521709 and GB2539986, application 1601505.9 due to grant in Q3 2017.
  • PCT applications WO 2015/022509, WO 2016/120617, WO2017/060685
  • US applications US2015/0051441, US2016-0213749 and US 2017/0095536


Trademarking for 'Ostara™’ and ‘ProgenySys™’ are registered trademarks of Ostara Biomedical.

Ostara also have industrial design rights on it’s novel Controlled Dose Delivery System.

Quality Policy

Ostara Biomedical Limited is committed to understanding and meeting the quality needs of all our customers. As a basic business principle, we strive to provide our customers with quality, innovative products and services.
All work performed by Ostara Biomedical has been done, and will be done, in accordance with the Council of Europe’s Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific purposes and has only worked with, and in the future will only work with, partners who work in accordance with that same Convention.

We have established a comprehensive quality assurance system that will allow us to meet our commitment to
customer satisfaction, providing superior biomedical devices to our customers which:

  • Meet our customer’s expectation of quality with a goal of every product being our best product
  • Provide leadership in medical device innovation
  • Meet our customer’s expectation of on-time delivery
  • Comply with all applicable regulatory requirements

Continuous quality improvement is the responsibility of every company employee and we build quality
into everything we do.




Ostara Biomedical Limited, Liverpool Science Park,
131 Mount Pleasant, Liverpool, L3 5TF